Global Drugs for Herpes Labialis (Oral Herpes) Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Drugs for Herpes Labialis (Oral Herpes) Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Herpes Labialis (Oral Herpes) is a type of herpes simplex occurring on the lip, i.e. an infection caused by herpes simplex virus (HSV). An outbreak typically causes small blisters or sores on or around the mouth. The sores typically heal within 2–3 weeks, but the herpes virus remains dormant in the facial nerves, following orofacial infection, periodically reactivating (in symptomatic people) to create sores in the same area of the mouth or face at the site of the original infection.
Drugs for Herpes Labialis (Oral Herpes) report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Drugs for Herpes Labialis (Oral Herpes) market is projected to reach US$ 3449.3 million in 2034, increasing from US$ 2458 million in 2022, with the CAGR of 4.9% during the period of 2024 to 2034. Demand from External Use and Oral are the major drivers for the industry.
Global Drugs for Herpes Labialis (Oral Herpes) key players include GSK, Novartis, Teva, Mylan, Cadila, etc. Global top five manufacturers hold a share about 55%. North America is the largest market, with a share about 35%, followed by Europe, with a share about 30 percent. In terms of product, Rx Drugs is the largest segment, with a share about 90%. And in terms of application, the largest application is Oral, followed by External Use, and Injection, etc.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Drugs for Herpes Labialis (Oral Herpes) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
GSK
Novartis
Teva
Mylan
Cadila
Apotex
Daewoong Pharmaceutical
Livzon
Luoxin
Med shine
Bayer (Campho Phenique)
Blistex
Kelun
Hikma
Haiwang
Carmex
Cipher
Segment by Type
Aciclovir
Valacyclovir
Famciclovir
Docosanol
Other
External Use
Oral
Injection
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Drugs for Herpes Labialis (Oral Herpes) market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Drugs for Herpes Labialis (Oral Herpes) introduction, etc. Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12QYResearch’s Conclusions of Drugs for Herpes Labialis (Oral Herpes) market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by QYResearch.
Drugs for Herpes Labialis (Oral Herpes) report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Drugs for Herpes Labialis (Oral Herpes) market is projected to reach US$ 3449.3 million in 2034, increasing from US$ 2458 million in 2022, with the CAGR of 4.9% during the period of 2024 to 2034. Demand from External Use and Oral are the major drivers for the industry.
Global Drugs for Herpes Labialis (Oral Herpes) key players include GSK, Novartis, Teva, Mylan, Cadila, etc. Global top five manufacturers hold a share about 55%. North America is the largest market, with a share about 35%, followed by Europe, with a share about 30 percent. In terms of product, Rx Drugs is the largest segment, with a share about 90%. And in terms of application, the largest application is Oral, followed by External Use, and Injection, etc.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Drugs for Herpes Labialis (Oral Herpes) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
GSK
Novartis
Teva
Mylan
Cadila
Apotex
Daewoong Pharmaceutical
Livzon
Luoxin
Med shine
Bayer (Campho Phenique)
Blistex
Kelun
Hikma
Haiwang
Carmex
Cipher
Segment by Type
Aciclovir
Valacyclovir
Famciclovir
Docosanol
Other
Segment by Application
External Use
Oral
Injection
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Drugs for Herpes Labialis (Oral Herpes) market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Drugs for Herpes Labialis (Oral Herpes) introduction, etc. Drugs for Herpes Labialis (Oral Herpes) Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12QYResearch’s Conclusions of Drugs for Herpes Labialis (Oral Herpes) market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices